Our data here demonstrate the ability of ETV:IDS to reverse skeletal dysplasia in our MPS II mouse model, as treatment was initiated at a stage in disease progression when deficits in bone morphology were already present. The gene discussed is IDS; the disease is mucopolysaccharidosis type 2.